Apimeds Pharmaceuticals US Announces 1-for-10 Reverse Stock Split

What Happened
Apimeds Pharmaceuticals US, Inc. (APUS) filed a Form 8-K (filed Sept 23, 2026) disclosing a Certificate of Amendment that implemented a one-for-ten (1-for-10) reverse stock split of its common stock and reduced the common stock par value from $0.01 to $0.001. The Reverse Stock Split became effective at 12:01 a.m. ET on July 24, 2026; stockholder written consent approving the split was obtained on December 1, 2025.

Key Details

• Pre-split outstanding common shares: 15,091,180; post-split outstanding shares: 1,509,118.
• An additional 33,506 shares were issued later to round up fractional holdings at the beneficial holder level through the Depository Trust Company.
• Authorized shares unchanged: 100,000,000 common and 10,000,000 preferred.
• Trading began on a split-adjusted basis on the NYSE American under ticker "APUS" on July 24, 2026; new CUSIP: 03771D201.
• Proportionate adjustments were made to outstanding equity awards and warrants and their exercise prices. The filing also notes Item 3.03 (material modification to rights of security holders) in connection with the Charter Amendment, where applicable.

Why It Matters
A reverse split reduces the number of shares outstanding and increases the per-share price proportionally; it does not change an investor’s percentage ownership (aside from rounding adjustments). For retail investors, this can affect per-share trading price, lot sizes, and the share count shown in brokerage accounts (rounded shares were converted into whole shares). Adjustments to stock options and warrants preserve their economic terms but will change the number of underlying shares and exercise prices on a proportional basis.